Bu çalışmada eksenatidin iştah ve metabolik bozukluklarla ilişkili olduğu bilinen hormonal özellikli peptidler olan ghrelin, FGF-21 ve GDF-15 üzerine etkilerini araştırmayı amaçladık.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Amaç: Glukagon Benzeri Peptid-1(GLP-1) benzeri etkileri olan eksenatid ve benzeri ilaçlar son yıllarda diyabet ve obezite tedavisinde sıklıkla kullanılmaktadır.
📊
Temel Bulgular & Veri:Amaç: Glukagon Benzeri Peptid-1(GLP-1) benzeri etkileri olan eksenatid ve benzeri ilaçlar son yıllarda diyabet ve obezite tedavisinde sıklıkla kullanılmaktadır.
💡
Sonuç & Katkı:Bu çalışmada eksenatidin iştah ve metabolik bozukluklarla ilişkili olduğu bilinen hormonal özellikli peptidler olan ghrelin, FGF-21 ve GDF-15 üzerine etkilerini araştırmayı amaçladık.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:obezite · eksenatid · ghrelin
Özet
Amaç: Glukagon Benzeri Peptid-1(GLP-1) benzeri etkileri olan eksenatid ve benzeri ilaçlar son yıllarda diyabet ve obezite tedavisinde sıklıkla kullanılmaktadır. Bu çalışmada eksenatidin iştah ve metabolik bozukluklarla ilişkili olduğu bilinen hormonal özellikli peptidler olan ghrelin, FGF-21 ve GDF-15 üzerine etkilerini araştırmayı amaçladık.
Abstract
Objective: Exenatide and similar drugs which have Glucagon Like Peptide-1(GLP-1) like effects have been used frequently in the treatment of diabetes and obesity in recent years. In this study we aimed to investigate the effects of exenatide on ghrelin, FGF-21 and GDF-15 which are known to be associated with appetite and metabolic disorders.
YILMAZ, M. Ö., ÖZCAN, O. (2022). Obez Tip 2 Diyabetik Hastalarda Eksenatid Tedavisinin Metabolik Parametreler, Ghrelin, GDF-15 ve FGF-21 Üzerine Etkileri. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, Cilt: 24 - Sayı: 1, 110–117. https://ajindex.com/articles/685667
Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300-4
Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996:4;379(6560):69-72
Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology. 2010;86(1):44-57
Guclu M, Kiyici S, Gul Z, Cavun S. Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus. Endocr Connect. 2018;7(1):193-98
Hu Y, Liu J, Zhang H, Xu Y, Hong T, Wang G. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Metab. 2016;42(5):358-63
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-60
Van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004;25(3):426-57
Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86(10):5083-6
Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235-53
Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators--a critical appraisal. Cell Metab. 2012;16(6):693-705
Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-b family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 2013;24(4):373-84
Adela R, Banerjee SK. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res. 2015;2015.490842
Kempf T, Guba-Quint A, Torgerson J, Magnone MC, Haefliger C, Bobadilla M et al. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. Eur J Endocrinol. 2012;167(5):671-8
Hong JH, Choi YK, Min BK, Park KS, Seong K, Lee IK et al. Relat